drugset / Trial / NCT04514393
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Phase 2
Unknown
33 enrolled
Huiqiang Huang
Guangdong 999 Brain Hospital · collabNanfang Hospital, Southern Medical University · collabXian-Janssen Pharmaceutical Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to test the efficacy and tolerability of a combination treatment of methotrexate, ibrutinib, and temozolomide (MIT regimen) in treating patients who have newly-diagnosed primary CNS lymphoma.
Timeline
- Start
- 2020-10-10
- Primary completion
- 2022-09-01
- Completion
- 2024-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |
| Subject | Methotrexate | Small molecule | 3.5 g | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |